伊布替尼
套细胞淋巴瘤
癌症研究
敌手
淋巴瘤
化学
生物
内科学
医学
白血病
生物化学
慢性淋巴细胞白血病
受体
作者
Baohua Sun,Bhavin Shah,Warren Fiskus,Jun Qi,Kimal Rajapakshe,Cristian Coarfa,Li Li,Santhana G.T. Devaraj,Sunil Sharma,Liang Zhang,Michael Wang,Dyana T. Saenz,Stephanie Krieger,James E. Bradner,Kapil N. Bhalla
出处
期刊:Blood
[Elsevier BV]
日期:2015-08-08
卷期号:126 (13): 1565-1574
被引量:106
标识
DOI:10.1182/blood-2015-04-639542
摘要
Key Points BA reduces MYC, CDK4/6, nuclear RelA, and BTK expression and is synergistically lethal with ibrutinib in MCL cells. Cotreatment with BA and inhibitor of BCL2, CDK4/6, or histone deacetylases is synergistically lethal against ibrutinib-resistant MCL cells.
科研通智能强力驱动
Strongly Powered by AbleSci AI